TABLE 1.
Serial passage of CRSV virion preparations to examine defects in systemic movement and disassembly
| Inoculum | Leaf tissuea | Treatment prior to passagingb | Symptom
|
|
|---|---|---|---|---|
| Inoculated | Noninoculated | |||
| Mock inoculated | NI | — | − | − |
| CRSV 1.26 plus RNA-2 | NI | — | − | − |
| CRSV 1.30 plus RNA-2 | NI | — | + | + |
| Mock inoculated | I | — | − | − |
| Mock inoculated | I | RNase A | − | − |
| CRSV 1.26 plus RNA-2 | I | — | + | − |
| CRSV 1.26 plus RNA-2 | I | RNase A | + | − |
| CRSV 1.30 plus RNA-2 | I | — | + | + |
| CRSV 1.30 plus RNA-2 | I | RNase A | + | + |
a
Leaf tissue source of virion preparation. NI, upper, noninoculated tissue; I, inoculated tissue.
b
Treatment of virion preparations performed to prevent infection by unencapsidated viral RNA. —, no treatment; RNase A, 1 μg of RNase A for 10 min at 25°C.